ES2130672T3 - Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes. - Google Patents

Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.

Info

Publication number
ES2130672T3
ES2130672T3 ES95937008T ES95937008T ES2130672T3 ES 2130672 T3 ES2130672 T3 ES 2130672T3 ES 95937008 T ES95937008 T ES 95937008T ES 95937008 T ES95937008 T ES 95937008T ES 2130672 T3 ES2130672 T3 ES 2130672T3
Authority
ES
Spain
Prior art keywords
antigen
autoimmune diseases
peptides derived
immunotherapy
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937008T
Other languages
English (en)
Inventor
Anna Maria Helena Boots
Gijsbertus Francisc Verheijden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2130672T3 publication Critical patent/ES2130672T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS PEPTIDOS DERIVADOS DEL AUTOANTIGENO HC GP-39, DICHOS PEPTIDOS COMPRENDIENDO AL MENOS UNA DE LAS SECUENCIAS DE AMINOACIDO FGRSFTLAS (N 1), FTLASSETG (N NTQ (N LAS T RESTRINGIDAS MHC CLASE II PRESENTES EN EL AUTOANTIGENO HC GP-39 EN CARTILAGO ARTICULAR. HC GP-39 Y DICHOS PEPTIDOS PUEDEN SER UTILIZADOS EN UN TRATAMIENTO ESPECIFICO ANTIGENO DE LA DESTRUCCION DEL CARTILAGO ARTICULAR EN ENFERMEDADES AUTOINMUNES PARA INDUCIR LA TOLERANCIA DEL SISTEMA INMUNE. EL AUTOANTIGENO HC GP-39 Y DICHOS PEPTIDOS SON TAMBIEN ADECUADOS PARA INDUCIR ARTRITIS EN ANIMALES NO HUMANOS, PREFERIBLEMENTE RATONES. LA INVENCION ADEMAS SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHO AUTOANTIGENO Y/O DICHOS PEPTIDOS, A UN METODO DE DIAGNOSTICO PARA LA DETECCION DE CELULAS T AUTOREACTIVAS EN UNA MUESTRA DE PRUEBA Y EQUIPOS DE PRUEBA PARA UTILIZAR EN DICHO METODO.
ES95937008T 1994-10-27 1995-10-25 Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes. Expired - Lifetime ES2130672T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203128 1994-10-27
EP95200886 1995-04-07

Publications (1)

Publication Number Publication Date
ES2130672T3 true ES2130672T3 (es) 1999-07-01

Family

ID=26136688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937008T Expired - Lifetime ES2130672T3 (es) 1994-10-27 1995-10-25 Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.

Country Status (23)

Country Link
US (1) US5736507A (es)
EP (1) EP0733065B1 (es)
JP (1) JP3755894B2 (es)
KR (1) KR100485979B1 (es)
CN (1) CN1161379C (es)
AT (1) ATE177756T1 (es)
AU (1) AU696827B2 (es)
BR (1) BR9506377A (es)
CA (1) CA2173874A1 (es)
DE (1) DE69508380T2 (es)
DK (1) DK0733065T3 (es)
ES (1) ES2130672T3 (es)
FI (1) FI118472B (es)
GR (1) GR3030296T3 (es)
HU (1) HU218027B (es)
IL (1) IL115744A (es)
MX (1) MX9602495A (es)
NO (1) NO316703B1 (es)
NZ (1) NZ295659A (es)
PL (1) PL183761B1 (es)
RU (1) RU2178797C2 (es)
TR (1) TR199501326A2 (es)
WO (1) WO1996013517A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6881824B1 (en) 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
NZ334714A (en) * 1996-09-18 2000-08-25 Zetesis Spa Liver proteins as agents against autoimmune diseases
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
BR9912378A (pt) * 1998-07-23 2001-04-17 Akzo Nobel Nv Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição para diagnóstico.
WO2000004917A2 (en) * 1998-07-23 2000-02-03 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
EP1137411B1 (en) * 1998-12-09 2006-12-06 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Palladium-substituted bacteriochlorophyll derivatives and use thereof
CA2386398A1 (en) * 1999-10-18 2001-04-26 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
JP2006508014A (ja) * 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
RU2302872C9 (ru) * 2006-06-22 2008-12-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее функции хрящевой ткани, и способ его получения
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
HRP20150317T1 (hr) 2009-02-05 2015-04-24 Circassia Limited Peptidi trave za cjepivo
AU2010311515B2 (en) * 2009-10-27 2014-02-20 Erytech Pharma Composition to induce specific immune tolerance
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CA3023092A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6323898A (ja) * 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
GB9125024D0 (en) * 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
JPH07506810A (ja) * 1992-02-10 1995-07-27 デューク・ユニバーシティ 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
AU4920093A (en) * 1992-09-14 1994-04-12 Brigham And Women's Hospital Reagents and methods for treating rheumatoid arthritis
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices

Also Published As

Publication number Publication date
PL183761B1 (pl) 2002-07-31
EP0733065B1 (en) 1999-03-17
WO1996013517A1 (en) 1996-05-09
ATE177756T1 (de) 1999-04-15
HUT74847A (en) 1997-02-28
IL115744A0 (en) 1996-01-19
AU3925295A (en) 1996-05-23
KR960705848A (ko) 1996-11-08
AU696827B2 (en) 1998-09-17
HU218027B (hu) 2000-05-28
IL115744A (en) 2000-07-16
NZ295659A (en) 1998-02-26
CA2173874A1 (en) 1996-05-09
RU2178797C2 (ru) 2002-01-27
BR9506377A (pt) 1997-09-16
FI962619L (fi) 1996-06-25
NO316703B1 (no) 2004-04-13
CN1161379C (zh) 2004-08-11
TR199501326A2 (tr) 1996-06-21
DK0733065T3 (da) 1999-10-11
DE69508380D1 (de) 1999-04-22
DE69508380T2 (de) 1999-09-09
MX9602495A (es) 1997-05-31
GR3030296T3 (en) 1999-09-30
FI962619A0 (fi) 1996-06-25
KR100485979B1 (ko) 2006-01-27
EP0733065A1 (en) 1996-09-25
FI118472B (fi) 2007-11-30
NO962695D0 (no) 1996-06-26
JPH09507861A (ja) 1997-08-12
HU9601401D0 (en) 1996-07-29
NO962695L (no) 1996-06-26
US5736507A (en) 1998-04-07
CN1168677A (zh) 1997-12-24
JP3755894B2 (ja) 2006-03-15
HK1002012A1 (en) 1998-07-24
PL315198A1 (en) 1996-10-14

Similar Documents

Publication Publication Date Title
ES2130672T3 (es) Nuevos peptidos derivados de un antigeno y destinados para la inmunoterapia de las enfermedades autoinmunes.
PT1203817E (pt) Compostos e metodos para imunoterapia e le diagnostic de tuberculose
Sakaguchi et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
DE69201441D1 (de) Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
Metzler et al. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis.
Redwan COVID-19 pandemic and vaccination build herd immunity.
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
Sibilia Novel concepts and treatments for autoimmune disease: ten focal points
ATE548376T1 (de) Immunsystem-modulierende peptide aus hitzeschock- proteinen und deren verwendungen
DE69332956D1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
Glant et al. Mapping of arthritogenic/autoimmune epitopes of cartilage aggrecans in proteoglycan-induced arthritis
Ahsan A Brief History and Discovery of Autoimmunity
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
Mitsuzawa et al. Experimental allergic encephalomyelitis induced by basic protein with synthetic adjuvant in comparison with Freund's complete adjuvant: Role of antibodies in correlation with the clinicopathological features
Adorini et al. Inhibition of T cell activation by blockade of MHC class II molecules
Barker et al. T-cell subsets in autoimmune haemolytic anaemia
IT1255037B (it) Procedimento per la preparazione di vaccini basato sulla identificazione di sequenze amminoacidiche dell'antigene simili a sequenze amminoacidiche dell'organismo da immunizzare, e vaccini cosi'ottenibili.
Kantele Human immune response to oral typhoid vaccination reflected as circulating antibody-secreting cells.
Hanyecz Investigation of possible immunological mechanisms in the pathogenesis of a murine model of rheumatoid arthritis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 733065

Country of ref document: ES